company background image
1530 logo

3SBio SZSC:1530 Stock Report

Last Price

HK$6.05

Market Cap

HK$14.2b

7D

-1.6%

1Y

-9.0%

Updated

21 Dec, 2024

Data

Company Financials +

1530 Stock Overview

An investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. More details

1530 fundamental analysis
Snowflake Score
Valuation5/6
Future Growth3/6
Past Performance2/6
Financial Health6/6
Dividends3/6

My Notes

Capture your thoughts, links and company narrative

3SBio Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for 3SBio
Historical stock prices
Current Share PriceHK$6.05
52 Week HighHK$7.85
52 Week LowHK$4.91
Beta0.73
1 Month Change6.33%
3 Month Change6.14%
1 Year Change-9.02%
3 Year Change-8.47%
5 Year Change-36.85%
Change since IPO-22.93%

Recent News & Updates

Recent updates

Shareholder Returns

1530HK BiotechsHK Market
7D-1.6%-3.9%-0.5%
1Y-9.0%-5.7%19.9%

Return vs Industry: 1530 underperformed the Hong Kong Biotechs industry which returned -5.7% over the past year.

Return vs Market: 1530 underperformed the Hong Kong Market which returned 19.9% over the past year.

Price Volatility

Is 1530's price volatile compared to industry and market?
1530 volatility
1530 Average Weekly Movement6.8%
Biotechs Industry Average Movement11.1%
Market Average Movement8.8%
10% most volatile stocks in HK Market18.6%
10% least volatile stocks in HK Market4.1%

Stable Share Price: 1530 has not had significant price volatility in the past 3 months compared to the Hong Kong market.

Volatility Over Time: 1530's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19935,607Jing Louwww.3sbio.com

3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; Cipterbin, an anti-HER2 monoclonal antibody for the treatment of HER2-positive metastatic breast cancer; TNF, pre-filled aqueous injection solution. It also offers YISAIPU, the receptor fusion tumor necrosis factor inhibitor; Mandi-minoxidil tincture, an OTC external medicine for treating hair loss; EPIAO and SEPO, an erythropoietin injection; SPARIN, an injectable low-molecular-weight heparin calcium.

3SBio Inc. Fundamentals Summary

How do 3SBio's earnings and revenue compare to its market cap?
1530 fundamental statistics
Market capHK$14.25b
Earnings (TTM)HK$1.77b
Revenue (TTM)HK$8.98b

8.1x

P/E Ratio

1.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1530 income statement (TTM)
RevenueCN¥8.42b
Cost of RevenueCN¥1.18b
Gross ProfitCN¥7.24b
Other ExpensesCN¥5.58b
EarningsCN¥1.66b

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.70
Gross Margin85.94%
Net Profit Margin19.69%
Debt/Equity Ratio24.7%

How did 1530 perform over the long term?

See historical performance and comparison

Dividends

4.0%

Current Dividend Yield

33%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 02:58
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

3SBio Inc. is covered by 34 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sharon ShiBOCI Research Ltd.
Ruyi TangBOCI Research Ltd.
Difei YangCapstone Investments